Viewing Study NCT01860534


Ignite Creation Date: 2025-12-25 @ 2:21 AM
Ignite Modification Date: 2026-02-28 @ 10:38 PM
Study NCT ID: NCT01860534
Status: COMPLETED
Last Update Posted: 2016-01-14
First Post: 2013-05-20
Is NOT Gene Therapy: True
Has Adverse Events: True

Brief Title: "Eye Protection After Mydriatic Use for ROP Screening: Impact on Vitals Signs and Pain Scores"
Sponsor: The University of Texas Medical Branch, Galveston
Organization:

Study Overview

Official Title: "Eye Protection After Mydriatic Use for ROP Screening: Impact on Vitals Signs and Pain Scores"
Status: COMPLETED
Status Verified Date: 2014-05
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: Pupillary dilation induced by mydriatic agents during Retinopathy of Prematurity exams can persist for hours. Despite regular use of eye protection for mydriatic-induced light sensitivity for infants, children and adults, eye protection after mydriasis has not been addressed in neonates. This study examines the use of eye patches to protect the dilated pupil from light exposure and their impact on vital signs and pain scores. prevents tachycardia, tachypnea and discomfort in neonates after ROP screening.
Detailed Description: Pain management for Retinopathy of prematurity (ROP) screening focuses on pharmacological and non-pharmacological interventions during the actual eye examination. Management of pain related to increased light sensitivity during the post-mydriasis period has not been described.

This prospective, randomized study evaluated the impact of protecting the eyes from ambient light exposure post mydriasis. Vital signs and pain scales were recorded in infants randomized to either wear or not wear eye patches after mydriasis for their ROP exam. Infants less than 30 weeks gestational age or less than 1500 grams at birth were included. Standard statistical methods were used to compare vital signs and pain scores for each group at baseline, 1 and 3 hours after mydriasis.

Study Oversight

Has Oversight DMC: True
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: